BIOVENTIX PLC

Director's Dealing • Mar 31, 2023

National Storage Mechanism | Additional information

RNS Number : 0016V

BioVentix PLC

31 March 2023

Bioventix plc

("Bioventix" or the "Company")

Director/PDMR Shareholding

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, was notified on 31 March 2023 of the following transactions in its ordinary shares of 5 pence each ("Ordinary Shares"):

Director	Role	Ordinary Shares sold	Average sale price per Ordinary Share	Ordinary Shares subsequently held	Percentage of issued share capital subsequently held
Ian Nicholson and Persons Closely Associated	Non-Executive Chairman	2,500	3,900	13,000	0.2%

The notifications below, which have been made in accordance with the requirements of the Market Abuse Regulation, provide further details.

For further information please contact:

Bioventix plc Peter Harrison Bruce Hiscock	Chief Executive Officer Chief Financial Officer	Tel: 01252 728 001
finnCap Ltd Geoff Nash/Simon Hicks Alice Lane	Corporate Finance ECM	Tel: 020 7220 0500

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA")

a)

Name

Ian Nicholson

2.

Reason for the Notification

a)

Position/status

Chairman

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bioventix plc

b)

LEI

213800225MHX7LZQY108

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 5 pence each

Identification code

GB00B4QVDF07

b)

Nature of the transaction

Sale of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)	Volume(s)
3,877p	1,000

d)

Aggregated information:

·      Aggregated volume

·      Price

See 4(c)

e)

Date of the transaction

31 March 2023

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

1

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA")

a)

Name

Catherine Nicholson

2.

Reason for the Notification

a)

Position/status

PCA of Ian Nicholson, Chairman

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bioventix plc

b)

LEI

213800225MHX7LZQY108

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 5 pence each

Identification code

GB00B4QVDF07

b)

Nature of the transaction

Sale of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)	Volume(s)
3,915p	1,500

d)

Aggregated information:

·      Aggregated volume

·      Price

See 4(c)

e)

Date of the transaction

31 March 2023

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEADDFDLFDEFA